Hypermutation events co-localised with ERBB2 amplification were not identified in TCGA and ICGC PDAC cohorts (https://dcc.icgc.org/releases/release_28/Projects/, Supplementary Fig. 6b, c), suggesting the patient-specific nature of this observed tumour event. This evidence concerns the gene ERBB2 and neoplasm.